Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis

T Kalincik; V Jokubaitis; T Spelman; D Horakova; E Havrdova; M Trojano; J Lechner-Scott; A Lugaresi; A Prat; M Girard; P Duquette; P Grammond; C Solaro; F Grand’Maison; R Hupperts; J Prevost; P Sola; D Ferraro; M Terzi; E Butler; M Slee; A Kermode; M Fabis-Pedrini; P McCombe; M Barnett; C Shaw; S Hodgkinson; H Butzkueven

Journal article

Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis

T Kalincik, V Jokubaitis, T Spelman, D Horakova, E Havrdova, M Trojano, J Lechner-Scott, A Lugaresi, A Prat, M Girard, P Duquette, P Grammond, C Solaro, F Grand’Maison, R Hupperts, J Prevost, P Sola, D Ferraro, M Terzi, E Butler Show all

Multiple Sclerosis Journal | SAGE PUBLICATIONS LTD | Published : 2018

DOI: 10.1177/1352458517728812

Download PDF

Abstract

Objective: This propensity score–matched analysis from MSBase compared the effectiveness of cladribine with interferon β, fingolimod or natalizumab. Methods: We identified all patients with relapse-onset multiple sclerosis, exposure to the study therapies and ⩾1-year on-treatment follow-up from MSBase. Three pairwise propensity score–matched analyses compared treatment outcomes over 1 year. The outcomes were hazards of first relapse, disability accumulation and disability improvement events. Sensitivity analyses were completed. Results: The cohorts consisted of 37 (cladribine), 1940 (interferon), 1892 (fingolimod) and 1410 patients (natalizumab). The probability of experiencing a relapse on ..

View full abstract

University of Melbourne Researchers

Tomas Kalincik Author

Timothy Spelman Author

Melanie Bahlo Author

Related Projects (4)

TREATING PROGRESSIVE MULTIPLE SCLEROSIS

While there are numerous therapies for relapsing-remitting multiple sclerosis (MS), therapy for progressive MS remains elusive. This project..

SELECTING OPTIMAL TREATMENT FOR PATIENTS WITH MULTIPLE SCLEROSIS

Multiple sclerosis is the most common cause of neurological disability among young people. With the increasing choice of therapies, the goal..

PRECISION TREATMENT FOR MULTIPLE SCLEROSIS: MAXIMISING THE EFFECT OF IMMUNOMODULATORY THERAPY

Response to therapy varies greatly among patients with multiple sclerosis (MS). The current lack of individualised MS therapy may lead to su..

PRECISION THERAPY FOR NEUROLOGICAL DISEASES

Multiple sclerosis is the most common cause of neurological disability among young adults. The patients’ individual response to therapy is h..

Grants

Awarded by Merck

Funding Acknowledgements

The author(s) disclosed receipt of the following financial support for the research, authorship and/or publication of this article: This study was financially supported by National Health and Medical Research Council of Australia (project grants 1129189 and 1083539 and practitioner fellowship 1080518). The MSBase Foundation is a not-for-profit organisation that receives support from Merck, Biogen, Novartis, Roche, Bayer Schering, Sanofi Genzyme and Teva.